ContraVir Pharmaceuticals Inc.'s stockholders approved a reverse stock split of the company's issued and outstanding common stock at a March 9 annual meeting.
The split ratio will be determined by the board within a range of 1-for-5 and 1-for-20 and is expected to be implemented on or before Feb. 21, 2019.
